Navigation Links
ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:10/5/2009

s is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics
    Dr. Steve Pakola, CMO
    Tel: +
'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014   BioTE ... therapy using natural, bio-identical hormone pellets, today announced ... MD to the company.   Dr. Rouzier is joining ... physician.      Dr. Rouzier was residency ... UCLA and is a board certified emergency physician ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 The ... clear and concise visual representation of history, migration, and ... was always regaled by family history stories stemming from ... as the "old country." Pictures and 8mm home movies ... side of the family, and Steve ordered a test ...
(Date:7/22/2014)... SHENZHEN , Cina, 22 luglio 2014 ... di BGI, la maggiore organizzazione di genomica del mondo, ... di sequenziamento dell,intero esoma umano con base la piattaforma ... Complete Genomics, molto apprezzata nel settore per essere in ... 99.999% di precisione e una rilevazione altamente sensibile di ...
(Date:7/22/2014)...  Semler Scientific, Inc. (Nasdaq: SMLR ... that develops patented products that assist healthcare providers ... announced that it will report second quarter 2014 ... markets on July 25, 2014. Doug Murphy-Chutorian, M.D., chief executive ... at 11 a.m. EDT, July 25, 2014. The ...
Breaking Biology Technology:Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 2DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 3DNA Test from DNA Spectrum Shows Heritage Like a Map of the Past 4BGI Tech lancia un servizio di sequenziamento dell'intero esoma umano sulla piattaforma avanzata di Complete Genomics 2Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2
... ... heat transfer fluid is a thermally stable, economical and high-performance solution for operations with ... ... new Paratherm GLT™ heat transfer fluid is a thermally stable, economical and high-performance solution ...
... , , , PHILADELPHIA ... Citation Laureates -- researchers likely to be in contention for Nobel honors -- ... economics to be announced from October 5-12. , , ... predictions of Nobel Prize winners. , , Each ...
... , PASADENA, Calif., Sept. 23 Alexandria ... today that it is commencing an underwritten public offering of ... and UBS Investment Bank are acting as joint bookrunning managers ... Equities, Inc. expects to grant the underwriters a thirty-day option ...
Cached Biology Technology:Paratherm's New GLT Heat Transfer Fluid: Thermally Stable & Lower Minimum Startup Temperatures 2Thomson Reuters Predicts Nobel Laureates 2Thomson Reuters Predicts Nobel Laureates 3Thomson Reuters Predicts Nobel Laureates 4Thomson Reuters Predicts Nobel Laureates 5Thomson Reuters Predicts Nobel Laureates 6Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock 2Alexandria Real Estate Equities, Inc. Announces Public Follow-on Offering of 3,000,000 Shares of Common Stock 3
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
(Date:7/22/2014)... negative reputation as disease causing agents, some viruses ... help to shape the world we live in ... American Academy of Microbiology. , "Viruses participate in ... on the planet, from contributing to biogeochemical cycles, ... events," states Marilyn Roossinck of Pennsylvania State University, ...
(Date:7/22/2014)... much promise for treating damaged organs and tissues, but ... limiting their effectiveness. New methods are being developed and ... function after transplantation, as described in a Review article ... from Mary Ann Liebert, Inc., publishers. The article is ... website . , In the article ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Report on viruses looks beyond disease 2
... Going about their day-to-day business, bees have no need ... when Adrian Dyer from Monash University trained the fascinating insects ... they seemed to be able to do just that. But ... that the bees weren,t learning to recognise people. ,Because the ...
... Va. New advances for the detection of cancer ... Forest School of Biomedical Engineering and Science (SBES) are ... 2010 Royal Society of Chemistry,s magazine, " Lab on ... microfluidics. http://www.rsc.org/Publishing/Journals/lc/index.asp Microfluidics is the behavior ...
... deadline of February 4th is only one week ... most important international osteoporosis meeting of the year, ... abstract online:, http://www.iofwco-ecceo10.org/abstracts/ Abstracts ... Osteoporosis International, with opportunity for poster presentation. Authors ...
Cached Biology News:Bees recognize human faces using feature configuration 2Bees recognize human faces using feature configuration 3Advances in cancer detection research by Virginia Tech engineer featured in British magazine 2Advances in cancer detection research by Virginia Tech engineer featured in British magazine 3
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
NAK/TBK1 (CT) Affinity Purified Polyclonal Antibody...
... human cardiac troponin subunit T, a 31kDa protein ... contraction of cardiac muscle. It reacts with subunit ... It also cross-reacts with human skeletal troponin T ... Highly purified human cardiac troponin T ...
... is pleased to offer the ATTO-TAG ... detection of primary amines. Developed by ... the ATTO-TAG reagents are similar to ... (NDA) and anthracene-2,3-dicarboxaldehyde, all of which ...
Biology Products: